We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $4.7B invested in Neurocrine Biosciences in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 23

43% more capital invested

Capital invested by funds: $3.29B → $4.7B (+$1.41B)

29% more call options, than puts

Call options by funds: $36.2M | Put options by funds: $28.1M

28% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 72

5% more funds holding

Funds holding: 207 → 218 (+11)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
218
Holders Change
+11
Holders Change %
+5.31%
% of All Funds
5.72%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
35
Increased
92
Reduced
72
Closed
23
Calls
$36.2M
Puts
$28.1M
Net Calls
+$8.07M
Net Calls Change
-$28.1M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$43.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$33.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$21.2M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$20.2M
5
JHIU
Janus Henderson Investors US
Colorado
+$19.9M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$66.1M
2
PA
Perceptive Advisors
New York
-$22.7M
3
Jennison Associates
Jennison Associates
New York
-$19.2M
4
TCP
Tourbillon Capital Partners
New York
-$18M
5
Millennium Management
Millennium Management
New York
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
226
Globeflex Capital
California
– -$812K -20,400 Closed
MACM
227
March Altus Capital Management
Connecticut
– -$692K -17,386 Closed
SG Americas Securities
228
SG Americas Securities
New York
– -$651K -16,353 Closed
VKH
229
Virtu KCG Holdings
New York
– -$501K -12,592 Closed
SCM
230
Stevens Capital Management
Pennsylvania
– -$485K -12,189 Closed
PP
231
Paloma Partners
Connecticut
– -$356K -8,949 Closed
PSC
232
Piper Sandler & Co
Minnesota
– -$318K -8,000 Closed
ZIM
233
Zacks Investment Management
Illinois
– -$317K -7,969 Closed
QC
234
QCM Cayman
Texas
– -$284K -7,130 Closed
DTL
235
Dynamic Technology Lab
Singapore
– -$239K -6,000 Closed
PAM
236
Princeton Alpha Management
New Jersey
– -$214K -5,368 Closed
EMG
237
Ellington Management Group
Connecticut
– -$211K -5,300 Closed
NIMI
238
Natixis Investment Managers International
France
– -$102K -2,573 Closed
QT
239
Quantbot Technologies
New York
– -$85K -2,141 Closed
SEC
240
Seven Eight Capital
New York
– -$40K -1,000 Closed
KCPG
241
Kavar Capital Partners Group
Kansas
– +$254 +5 +71%
6 7 8 9
10

NBIX Hedge Fund Activity: Q4 2015 in Review

218 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2015, worth a combined $4.7B — up 43% from $3.29B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new NBIX positions and 23 closed out — a net gain of 12 holders — while 92 added to existing stakes and 72 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $43.9M. The largest seller was OrbiMed, cutting an estimated $66.1M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2015, up from 207 in Q3 2015.
  • Funds reported $4.7B of Neurocrine Biosciences stock for Q4 2015, up 43% quarter-over-quarter.
  • 35 funds opened new Neurocrine Biosciences positions in Q4 2015 and 23 closed out, a net change of +12 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2015 was T. Rowe Price Associates, an estimated $43.9M added.
  • The largest Neurocrine Biosciences seller in Q4 2015 was OrbiMed, an estimated $66.1M sold.

Based on aggregated 13F filings for Q4 2015.